Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03940742 · ClinicalTrials.gov registry record · Phase 1
A Study of Tirzepatide in Participants With Impaired Liver Function
A Phase 1 study of Hepatic Insufficiency, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 3
- Study locations
NCT03940742: Completed Phase 1 study of Hepatic Insufficiency, sponsored by Eli Lilly and Company.
NCT03940742 is a Phase 1 study of Hepatic Insufficiency that has completed, run by Eli Lilly and Company. The registered enrollment target is 32 participants, below the 38-participant average among 14 other Hepatic Insufficiency trials with a reported enrollment target (16% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03940742, a Phase 1 study of Hepatic Insufficiency, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired liver function compared to healthy participants. The study will last about two months and will include five visits to the study center.
Primary Outcome
Pharmacokinetics (PK): Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC\[0-∞\]) of Tirzepatide.
Conditions Studied
Interventions
- DRUG Tirzepatide
Study Locations (3)
California
- Orange County Research Center - Tustin
Florida
- Orlando Clinical Research Center - Orlando
Louisiana
- New Orleans Center for Clinical Research - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2019-07-22 |
| Est. Completion | 2020-09-22 |
| Phase | Phase 1 |
What the finished NCT03940742 record still lists
NCT03940742 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 38-participant average among 14 other Hepatic Insufficiency trials with a reported enrollment target (16% lower).
The record links to 1 condition, with Hepatic Insufficiency appearing as the primary indexed condition, and to 1 intervention - of which Tirzepatide is the first listed.
NCT03940742 reports a single indexed study location in California, Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT03940742 about?
NCT03940742 is a clinical study titled "A Study of Tirzepatide in Participants With Impaired Liver Function". The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired liver function compared to healthy participants. The study will last about two months and will include five visits to the study center.
What is the current status of trial NCT03940742?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2019-07-22. Estimated completion is 2020-09-22.
What conditions does trial NCT03940742 study?
This clinical trial studies the following conditions: Hepatic Insufficiency.
What interventions are being tested in trial NCT03940742?
The interventions under investigation include: Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT03940742?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03940742 being conducted?
This trial has 3 study locations across California, Florida, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatic Insufficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03940742's enrollment target sits among peer trials
32 8th of 14 higher than 4 of 14 other Hepatic Insufficiency trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatic Insufficiency trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
RECRUITING · Phase 1
-
A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.
RECRUITING · Phase 1
-
Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug
COMPLETED · Phase 1
-
A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants
COMPLETED · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI